Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patientsYasuhiro Nakamura, N. Yamazaki, Takeru Funakoshi et al.|Annals of Oncology|2020Cited by 140
Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanomaYasuhiro Fujisawa, Norito Katoh, Shusuke Yoshikawa et al.|Cancer Medicine|2019Cited by 111
Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)Yasuhiro Nakamura, Naoya Yamazaki, Kenjiro Namikawa et al.|ESMO Open|2021Cited by 57
Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging systemYasuhiro Fujisawa, Norito Katoh, Shusuke Yoshikawa et al.|Journal of Dermatological Science|2019Cited by 26
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Keith T. Flaherty, Shaheen Ahmed et al.|EClinicalMedicine|2023Cited by 26